Trending
The Situational Awareness fund had 56% in two AI stocks and 75%+ in five total when a 2026 sector correction hit. A look at what the structure exposed.
The ECB warned Monday that a U.S. tech stock correction tied to AI exuberance is likely, with limited fiscal and monetary tools available to cushion the hit.
Archer Aviation projects losses up to $200M per quarter with $1.6B in cash, giving it roughly 8 quarters before funds run out. FAA certification is the key milestone.
Eight-year-old Beckett Phelps is showing interest in swimming, with early guidance from Bob Bowman, the coach who built his father Michael Phelps’ career.
Luigi Mangione pleaded guilty to federal stalking charges ahead of his New York murder trial over the killing of a UnitedHealthcare executive, set to begin next month.
Anthropic’s IPO valuation is built on a $190-200B revenue forecast for 2028, not current financials — a rare and aggressive Wall Street pricing move.
The ECB warned Monday that a U.S. tech stock correction tied to AI exuberance is likely, with limited fiscal and monetary tools available to cushion the hit.
Anthropic’s IPO valuation is built on a $190-200B revenue forecast for 2028, not current financials — a rare and aggressive Wall Street pricing move.
Just In
The Situational Awareness fund had 56% in two AI stocks and 75%+ in five total when a 2026 sector correction hit. A look at what the structure exposed.
U.S. stocks hit a record after July inflation data showed improvement, while Asian shares fell mostly lower and U.S. futures stayed little changed.
Trump’s vaccine executive order is raising alarms among pediatricians as measles spreads, immunization rates fall, and children return to school.
Clothing retailers are offering repairs and sewing workshops to attract Gen Z shoppers motivated by both saving money and reducing environmental waste.
Finance
Archer Aviation projects losses up to $200M per quarter with $1.6B in cash, giving it roughly 8 quarters before funds run out. FAA certification is the key milestone.
Editor's Picks
VanEck’s Pharma ETF offers lower costs and stability; Invesco’s Biotech ETF chases higher returns with steeper risk. Which fits your portfolio?
Latest
Boston Scientific director Habiger bought $100K in BSX shares, expanding his stake 14% as the stock sits near a 54% decline and multi-year lows.
